Synthesis method of dasatinib intermediate

Through the acylation of 2-aminothiazole-4-carboxylic acid and pivaloyl chloride and the condensation reaction of 2-chloro-6-methylaniline, the high raw material cost, low yield and environmental pollution in the synthesis of dasatinib intermediates are solved. The problem of high purity and high yield preparation is achieved, process operation is simplified and energy consumption is reduced.

CN118994050AActive Publication Date: 2024-11-22GAOYOU CITY ORGANIC CHEM FACOTRY
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202411096314.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

The existing synthesis method of dasatinib intermediate 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-formamide has problems with high raw material cost, low yield and low product purity. , and the process uses sulfoxide chloride that is volatile and has high environmental pollution and requires low pressure distillation, resulting in high energy consumption and strict equipment requirements.

Method used

2-aminothiazole-4-carboxylic acid reacts with valeryl chloride to form mixed anhydride, and condenses with 2-chloro-6-methylaniline, and then hydrolyzes to obtain high-purity 2-amino-N-(2-chloro-6- Methylphenyl)thiazole-5-formamide improves reaction selectivity and by-product removal convenience by adjusting reaction conditions and acid binding agent selection.

Benefits of technology

The preparation of dasatinib intermediates with high purity and high yield is achieved, which reduces raw material costs, simplifies process operations, avoids energy consumption and environmental pollution problems in the prior art, and improves the economic and social benefits of the process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994050A_ABST
    Figure CN118994050A_ABST
Patent Text Reader

Abstract

The invention discloses a synthetic method of a dasatinib intermediate, which belongs to the technical field of organic synthesis, and comprises the following steps: by taking 2-aminothiazole-4-formic acid as a raw material, firstly generating mixed anhydride with pivaloyl chloride in situ, then further performing condensation reaction with 2-chloro-6-methylaniline, and finally obtaining the dasatinib intermediate. And the obtained compound 2 is not separated and is directly hydrolyzed to obtain the high-purity 2-amino-N-(2-chloro-6-methylphenyl) thiazole-5-formamide. The mixed anhydride formed by pivaloyl chloride has large steric hindrance, further reaction with corresponding amine is beneficial to regioselectivity, and the byproduct pivaloyl acid can be easily removed through post-treatment, so that the defects in the prior art are overcome, the unit operation involved in the whole preparation process is simpler, and the cost is lower. And the product has high purity and yield, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of organic synthesis, and in particular to a method for synthesizing a dasatinib intermediate. Background Art

[0002] Dasatinib intermediate: 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide, English name: 2-amino-N-(2-methyl-6-chlorophenyl)thiazole-5-carboxamide, its CAS Registry Number(s): 302964-24-5, melting point is 258-262℃, chemical structure is as follows:

[0003]

[0004] 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide is a key intermediate for the synthesis of dasatinib. Dasatinib (Dasatinib, trade name Sprycel) is an oral tyrosine kinase inhibitor developed by Bristol-Myers Squibb. The drug was approved by the FDA in June 2006 for the treatment of chronic myeloid leukemia and can also treat Philadelphia chromosome-positive acute lymphoblastic leukemia. BMS disclosed in an annual document that due to a settlement agreement with Apotex and some undisclosed companies, generic drugs may be launched in September 2024 or earlier. So far, generic drugs from Biocon, Lupin, Dr. Reddy's Laboratories, Alebmic and Teva have all been approved by the FDA.

[0005] The synthesis of 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide in the prior art is as follows:

[0006] 1. Patent US200737978 uses 2,3-dichloroacrylic acid and thionyl chloride to form an acyl chloride, which is then connected with 2-chloro-6-methylaniline, and then treated with methanol-sodium methoxide to generate dimethyl acetal. Finally, it is deprotected under acidic conditions and in situ ring-closed with thiourea to obtain the target compound.

[0007] Reaction:

[0008]

[0009] The reaction process involves the synthesis of 2,3-dichloroacryloyl chloride, which is easily polymerized and requires vacuum distillation, high energy consumption and equipment requirements, and uses volatile chlorinated reagents such as thionyl chloride that are relatively polluting to the environment.

[0010] 2. WO2017 / 2131,2017,A1 and WO2005077945A2 react 3-ethoxyacryloyl chloride with 2-chloro-6-methylaniline to obtain N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide, which is then reacted with NBS and thiourea to obtain the target compound.

[0011] Reaction:

[0012]

[0013] The compound 3-ethoxyacryloyl chloride is easy to polymerize, resulting in reduced yield and impure intermediate products. It needs to be purified by vacuum distillation, and the energy consumption requires high equipment. In addition, the large-scale use of NBS must be carried out at low temperatures, which greatly increases the cost and harsh conditions, and also increases the workload of post-processing.

[0014] 3. [Synthetic Communications, 2017, vol. 47, #17, p. 1610-1621] and patent US2004 / 54186 both use oxalyl chloride to first prepare acyl chloride, which is then reacted with 2-chloro-6-methylaniline in the presence of diisopropylethylamine, with a maximum separation yield of 51%; Chinese patent CN106279061, 2017, A uses 2-tert-butyloxycarbonylaminothiazole-5-carboxylic acid to react with thionyl chloride, which is then reacted with 2-chloro-6-methylaniline in the presence of pyridine, and finally the protecting group is removed to obtain the target compound.

[0015] Reaction:

[0016]

[0017] First, carboxylic acid is converted into acyl chloride, and then the acyl chloride is reacted with amine to prepare amide. The yield of synthesizing amide by this method should be relatively high in theory, but the preparation yield of the intermediate reported in the current patents is relatively low. Therefore, it is necessary to further study the preparation method of the intermediate to improve the yield and reduce the cost.

[0018] In summary, finding a method for synthesizing 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide with "low raw material cost, high product purity and yield, and less three wastes" has become a technical problem that needs to be urgently solved in the field. Summary of the invention

[0019] In view of this, the present invention proposes a method for synthesizing a dasatinib intermediate, aiming to improve product purity and yield, reduce the raw material cost of dasatinib, and obtain better economic and social benefits.

[0020] The technical solution of the present invention is achieved as follows: The present invention provides a method for preparing a dasatinib intermediate, the intermediate is 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide, and the preparation method comprises the following steps:

[0021] Step 1, preparing compound 1 represented by formula I by reacting 2-aminothiazole-4-carboxylic acid and pivaloyl chloride;

[0022] Step 2: Compound 1 represented by formula I is reacted with 2-chloro-6-methylaniline to obtain compound 2 represented by formula II;

[0023] Step 3: hydrolyze the compound 2 shown in formula II to prepare 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide;

[0024] Wherein compound 1 is formula I:

[0025] Compound 2 is of formula II:

[0026] The specific reaction route of the above reaction is as follows:

[0027]

[0028] In step 1, 2-aminothiazole-4-carboxylic acid is acylated with pivaloyl chloride to prepare compound 1, and then compound 1 is reacted with 2-chloro-6-methylaniline. Since the mixed anhydride formed by pivaloyl chloride has high reactivity and large steric hindrance, further condensation reaction with the corresponding amine is beneficial to regional selectivity, thereby improving the purity of the target product. At the same time, the by-product pivalic acid is easy to remove, which is beneficial to simplifying the operation.

[0029] In some embodiments, the molar ratio of 2-aminothiazole-4-carboxylic acid to pivaloyl chloride is 1:(2-4), and the molar ratio of 2-aminothiazole-4-carboxylic acid to 2-chloro-6-methylaniline is 1:(1-2), preferably 1:1.

[0030] In some embodiments, step 1 specifically comprises: adding 2-aminothiazole-4-carboxylic acid to tetrahydrofuran under a nitrogen atmosphere, stirring and cooling to 0-10° C., adding an acid binding agent, adding pivaloyl chloride dropwise while maintaining the temperature, and stirring the reaction to obtain a reaction solution containing compound 1 shown in formula I after the addition is completed.

[0031] In some embodiments, the acid-binding agent includes any one of triethylamine, diisopropylethylamine, pyridine and N-methylmorpholine.

[0032] In some embodiments, in step 1, the method for judging whether the reaction is complete includes: sampling and testing, and the reaction is complete when the weight content is calculated as 2-aminothiazole-4-carboxylic acid / (2-aminothiazole-4-carboxylic acid + compound 1) ≤ 1%.

[0033] In some embodiments, step 2 further includes adding 2-chloro-6-methylaniline to the obtained reaction solution containing compound 1 shown in formula I, controlling the reaction temperature to 0-10°C, and stirring at the temperature until the reaction is complete to obtain a reaction solution containing compound 2 shown in formula II.

[0034] In some embodiments, in step 2, the method for judging whether the reaction is complete includes: taking samples for testing, and the reaction is complete when the weight content is calculated as Compound 1 / (Compound 1+Compound 2) ≤ 1%.

[0035] In some embodiments, step three further includes adding aqueous sodium hydroxide solution to the obtained reaction solution containing compound 2 shown in formula II, heating to 10-100° C., stirring at this temperature until the reaction is complete, adjusting the pH to 5-7 with hydrochloric acid, cooling to 20-30° C., filtering and collecting the filter cake to obtain 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide.

[0036] In some embodiments, in step three, the heating temperature is preferably 50-60°C.

[0037] In some embodiments, in step three, the method for judging whether the reaction is complete includes: sampling and testing, and the reaction is complete when the weight content is calculated as Compound 2 / (Compound 2+2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide) ≤ 1%.

[0038] In some embodiments, the process further comprises step 4, mixing the 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide obtained in step 3 with a crystallization solvent, heating the mixture to 70-80° C., stirring the mixture until the solution is clear, then cooling the mixture to 0-5° C., filtering and collecting the solid to obtain refined 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide.

[0039] In some embodiments, in step 4, the crystallization solvent comprises one of ethanol, tetrahydrofuran, isopropanol, ethyl acetate and isopropyl acetate.

[0040] Compared with the prior art, the present invention has the following beneficial effects:

[0041] The invention uses 2-aminothiazole-4-carboxylic acid and pivaloyl chloride to generate a mixed anhydride in situ, and after a condensation reaction with 2-chloro-6-methylaniline, the obtained compound is directly hydrolyzed in the form of a reaction solution to obtain a high-purity target product. The process is simple to operate and has a high yield. The mixed anhydride formed by pivaloyl chloride has a large steric hindrance, and further reaction with the corresponding amine is beneficial to regional selectivity, and the byproduct pivalic acid can be easily removed by post-treatment, thereby forming a preparation process that solves the defects of the prior art process and leads the industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0043] Figure 1 The HPLC spectrum of the product prepared in Example 1 is shown in FIG. DETAILED DESCRIPTION

[0044] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0045] Unless otherwise specified, the methods used in the following examples are all conventional methods. Unless otherwise specified, the materials, reagents and instruments used are all conventional materials, reagents and instruments in the art, and can be obtained by those skilled in the art through commercial channels.

[0046] When an amount, concentration or other value or parameter is expressed as a range, a preferred range or a range defined by a series of upper preferred values ​​and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when a range of "1 to 5" is disclosed, the described range should be interpreted as including the range "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5", etc. When a numerical range is described herein, unless otherwise stated, the range is intended to include its end values ​​and all integers and fractions within the range. In the present specification and claims, range definitions can be combined and / or interchanged, and if not otherwise stated, these ranges include all subranges contained therein.

[0047] The existing technologies mainly include: US BSM Company in US2004 / 54186 uses oxalyl chloride to first prepare acyl chloride, and then reacts with 2-chloro-6-methylaniline in the presence of diisopropylethylamine for 24 hours, with a separation yield of 48%; Shanghai Kesheng in CN106279061, 2017, A uses 2-tert-butoxycarbonylaminothiazole-5-carboxylic acid and thionyl chloride to react, and then reacts with 2-chloro-6-methylaniline in the presence of pyridine, and finally removes the protecting group to obtain the target product 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide.

[0048] When 2-tert-butyloxycarbonylaminothiazole-5-carboxylic acid is used as a raw material, the protective group Boc is easily partially removed during the reaction to obtain impurity 1, and further reaction of impurity 1 and 2-chloro-6-methylaniline can obtain impurity 2, making it difficult to purify the product and obtain a high-purity product. This is a technical problem that needs to be solved in the current prior art.

[0049] The reaction equation of the side reaction is as follows:

[0050]

[0051] The invention provides a method for preparing a high-purity target product by directly hydrolyzing a compound obtained by in-situ generating a mixed anhydride from 2-aminothiazole-4-carboxylic acid and pivaloyl chloride and subjecting the mixed anhydride to a condensation reaction with 2-chloro-6-methylaniline in the form of a reaction solution. The mixed anhydride formed by pivaloyl chloride has a large steric hindrance, and further reaction with a corresponding amine is beneficial to regional selectivity, and the byproduct pivalic acid can be easily removed by post-treatment, thereby solving the process defects of the prior art.

[0052] Example 1

[0053] S1-1: In a reaction apparatus, 2-aminothiazole-4-carboxylic acid (14.5 g, 0.1 mol) was added to 50 ml of tetrahydrofuran under nitrogen protection, and the mixture was stirred and cooled to 5°C, and N-methylmorpholine (25.2 g, 0.25 mol) was added; pivaloyl chloride (26.5 g, 0.22 mol) was added dropwise at 0-10°C, and after the addition was completed, the mixture was kept in the range of 0-10°C, stirred, and kept warm for reaction. Samples were taken for testing. When the test results showed that 2-aminothiazole-4-carboxylic acid / (2-aminothiazole-4-carboxylic acid + compound 1) was ≤1% by weight content, the reaction was complete; 2-chloro-6-methylaniline (14.2 g, 0.1 mol) was added, the temperature was controlled to 0-10°C, the mixture was kept warm for reaction, samples were taken for testing. When the test results showed that compound 1 / (compound 1 + compound 2) was ≤1.0% by weight content, the reaction was terminated;

[0054] S1-2: Add 20% sodium hydroxide aqueous solution (50 g, 0.25 mol) to the reaction solution, raise the temperature to 55°C, keep the temperature for reaction, take samples for testing, and when the test results show that the weight content of the compound of formula II 2 / (compound of formula II 2+2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide) is ≤1.0%, terminate the reaction; adjust the pH to 6.2 with hydrochloric acid, cool to 25°C, collect the solid by filtration, and wash with water to obtain a crude product;

[0055] S1-3: Under nitrogen protection, the crude product prepared in step S1-2 and 100 ml of isopropyl acetate were added to the reaction apparatus, and the temperature was raised to 75°C. After the solution was clarified, the temperature was lowered to 2°C, and the solid was collected by filtration. The obtained wet solid was dried under reduced pressure to obtain 25.8 g of product. The HPLC results were as follows: Figure 1 As shown, the purity of the target product 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide is 99.9% and the molar yield is 96.0%.

[0056] Example 2-Example 4 Based on Example 1, only the type of acid binding agent was changed, and other conditions remained unchanged.

[0057] The data of different acid binding agents and product yield and purity in Examples 1-5 are as follows:

[0058] Grouping Reactive acid binder Yield (%) purity(%) Example 1 N-Methylmorpholine 96.0 99.9 Example 2 Triethylamine 92.6 99.7 Example 3 Diisopropylethylamine 92.5 99.6 Example 4 Pyridine 91.3 99.8 Example 5 N,N-Dimethylaniline 93.2 99.5

[0059] The difference between Example 6-12 and Example 1 is that the reaction temperature in step S1-2 is different, and other conditions remain unchanged. The specific reaction conditions and product yield and purity data are as follows:

[0060] Grouping Step S1-2 Reaction Temperature Yield (%) purity(%) Example 6 5 -(No reaction) - Example 7 10 85.6 97.2 Example 8 30 88.3 98.2 Example 9 50 93.6 99.6 Example 10 60 95.3 99.5 Embodiment 11 80 89.0 99.1 Example 12 100 76.0 98.2 Example 1 55 96.0 99.9

[0061] Based on the above data, it can be seen that the optional reaction temperature is 10-100°C, preferably 50-60°C.

[0062] The difference between Example 13 to Example 16 and Example 1 is that the selection of the crystallization solvent in step S1-3 is different, and the other conditions are the same. The specific crystallization solvent selection and the product yield and purity data are as follows:

[0063] Grouping Step S1-3 Crystallization solvent Yield (%) purity(%) Embodiment 13 Ethanol 89.1 99.7 Embodiment 14 Tetrahydrofuran 86.6 99.8 Embodiment 15 Isopropyl alcohol 91.9 99.6 Example 16 Ethyl acetate 92.5 99.6 Example 1 Isopropyl acetate 96.0 99.9

[0064] It can be seen from the above data that the crystallization solvent in step S1-3 can be selected from ethanol, tetrahydrofuran, isopropanol, ethyl acetate and isopropyl acetate, preferably isopropyl acetate.

[0065] The only difference between Example 17 to Example 19 and Example 1 is that the molar ratio of 2-aminothiazole-4-carboxylic acid to pivaloyl chloride is different.

[0066]

[0067] The above data show that the molar ratio of 2-aminothiazole-4-carboxylic acid to pivaloyl chloride has good yield and purity at 1:(2-4), but the best effect is achieved at 1:2.2.

[0068] The only difference between Example 20 and Example 21 and Example 1 is that the molar ratio of 2-aminothiazole-4-carboxylic acid to 2-chloro-6-methylaniline is different.

[0069]

[0070] From the above data, it can be seen that the molar ratio of 2-aminothiazole-4-carboxylic acid to 2-chloro-6-methylaniline has good yield and purity at 1:(1-2), but 1:1 is the best and has the lowest material cost.

[0071] Comparative Example 1

[0072] This comparative example repeats the technical solution of CN106279061, 2017, A and Synthetic Communications, 2017, vol.47, #17, p.1610-1621:

[0073]

[0074] S1-S2: According to the preparation method of CN106279061,2017,A

[0075] S1: Add 2-tert-butoxycarbonylaminothiazole-5-carboxylic acid (50 g, 0.20 mol), dichloromethane (1 L), N,N-dimethylformamide (1.5 g, 0.02 mol) and thionyl chloride (48 g, 0.4 mol) into reaction flask 1 in sequence, heat to 40 ° C for 1 hour, until the concentration of 2-tert-butoxycarbonylaminothiazole-5-carboxylic acid is less than 1%, evaporate the dichloromethane under reduced pressure, add chlorobenzene (800 ml) to dissolve, and set aside.

[0076] S2-1: Add pyridine (81 g, 1.0 mol), 2-chloro-6-methylaniline (24 g, 0.17 mol) and chlorobenzene (150 ml) to reaction flask 2, heat to 90-100°C, add the solution in reaction flask 1 dropwise, and complete the addition in about 35 minutes. Then react at 90-100°C until the concentration of 2-chloro-6-methylaniline is less than 0.5%.

[0077] S2-2: After the reaction is completed, the system is cooled to 0-10°C and stirred at this temperature for 2 hours. Filter to obtain a crude product as a light yellow solid. The solid is slurried with 150 ml of 2% sodium hydroxide aqueous solution and 250 ml of methanol for 3 hours. Filter and dry the solid at 50°C to obtain 52 g of a white solid with a yield of 80% and a HPLC purity of 98.12%.

[0078] S3: According to the preparation method of [Synthetic Communications, 2017, vol.47, #17, p.1610-1621]:

[0079] Trifluoroacetic acid (250.0 ml) was added to reaction flask 3, and tert-butyl (5-(((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)carbamate (25.0 g, 0.07 mol) was added under stirring, and stirred at 25-30° C. for 2 hours. The reaction was confirmed to be complete by HPLC, trifluoroacetic acid was distilled off, and the residue was diluted with ethyl acetate (250.0 ml). The ethyl acetate layer was washed with saturated NaHCO3 solution (2X 25.0 ml) and then with saturated NaCl solution (125.0 ml). The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated, and crystallized with methyl tert-butyl ether (250.0 ml) to obtain compound 1 (16.2 g, 89%). After testing, the HPLC purity was 97.56%.

[0080] The results of the comparative experiment show that the dasatinib intermediate 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide is obtained by operating according to the preparation method of Chinese patent CN106279061A and [Synthetic Communications, 2017, vol.47, #17, p.1610-1621]. The total yield of the three-step reaction is only 71.2% and the purity is 97.5%, which is much lower than the process of mixed anhydride formed by pivaloyl chloride used in the present invention, further illustrating that the technical effect of the present invention has significant improvements and innovations over the prior art.

[0081] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for synthesizing a dasatinib intermediate, wherein the dasatinib intermediate is 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide, characterized in that: The steps include: Step 1, preparing compound 1 represented by formula I by reacting 2-aminothiazole-4-carboxylic acid and pivaloyl chloride; Step 2: Compound 1 represented by formula I is reacted with 2-chloro-6-methylaniline to obtain compound 2 represented by formula II; Step 3: hydrolyze the compound 2 shown in formula II to prepare 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; I: II:

2. The method for synthesizing a dasatinib intermediate according to claim 1, wherein: Step 1 also includes adding 2-aminothiazole-4-carboxylic acid to tetrahydrofuran under a nitrogen atmosphere, stirring and cooling to 0-10° C., adding an acid binding agent, and adding pivaloyl chloride dropwise while keeping the temperature constant. After the addition is completed, stirring and reacting to obtain a reaction solution containing compound 1 shown in formula I.

3. The method for synthesizing a dasatinib intermediate according to claim 2, wherein: The acid-binding agent includes any one of triethylamine, diisopropylethylamine, pyridine and N-methylmorpholine.

4. The method for synthesizing a dasatinib intermediate according to claim 2, wherein: In step 1, the method for judging whether the reaction is complete includes: sampling and testing, and when the weight content is calculated and the 2-aminothiazole-4-carboxylic acid / (2-aminothiazole-4-carboxylic acid+compound 1) is ≤ 1%, the reaction is complete.

5. The method for synthesizing a dasatinib intermediate according to claim 2, wherein: Step 2 also includes adding 2-chloro-6-methylaniline to the obtained reaction solution containing compound 1 shown in formula I, controlling the reaction temperature to 0-10° C., and stirring at the temperature until the reaction is complete to obtain a reaction solution containing compound 2 shown in formula II.

6. The method for synthesizing a dasatinib intermediate according to claim 5, wherein: In step 2, the method for judging whether the reaction is complete includes: sampling and testing, and when the weight content is calculated and the compound 1 / (compound 1+compound 2) is ≤ 1%, the reaction is complete.

7. The method for synthesizing a dasatinib intermediate according to claim 5, wherein: Step three also includes adding aqueous sodium hydroxide solution to the obtained reaction solution containing compound 2 shown in formula II, heating to 10-100° C., stirring at this temperature until the reaction is complete, adjusting the pH to 5-7 with hydrochloric acid, cooling to 20-30° C., filtering and collecting the filter cake to obtain 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide.

8. The method for synthesizing a dasatinib intermediate according to claim 7, wherein: In step 3, the method for judging whether the reaction is complete includes: sampling and testing, and when the weight content is calculated, the reaction is complete when compound 2 / (compound 2+2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide) ≤ 1%.

9. The method for synthesizing a dasatinib intermediate according to claim 1, wherein: The method further comprises the step of mixing the 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide obtained in the step of step 3 with a crystallization solvent, heating the mixture to 70-80° C., stirring the mixture until the solution is clear, then cooling the mixture to 0-5° C., filtering and collecting the solid, and obtaining refined 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide.

10. The method for synthesizing a dasatinib intermediate according to claim 9, wherein: The crystallization solvent includes one of ethanol, tetrahydrofuran, isopropanol, ethyl acetate and isopropyl acetate.

Citation Information

Patent Citations

  • Method for preparing dasatinib intermediate

    CN106279061A

  • Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

    WO2005077945A2

  • Preparation method of dasatinib intermediate

    CN104119292A

  • Deuterated dasatinib, and preparation method and application thereof

    CN104130250A

  • Dasatinib derivative with anti-tumor activity and application thereof

    CN106674150A